U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07304518) titled 'Phase II Trial of PRT-064040 Nasal Spray for the Treatment of Migraine in Adults' on Dec. 03.
Brief Summary: The purpose of this study is to learn about the efficacy and safety of PRT-064040 Nasal Spray versus placebo in the acute treatment of moderate or severe migraine.
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Migraine
Intervention:
DRUG: PRT-064040 nasal spray
A single dose of PRT-064040 nasal spray
DRUG: Placebo
A single dose of placebo matched to PRT-064040 nasal spray
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Sichuan Purity Pharmaceutical Technology Co., Ltd.
Disclaimer: Curated by H...